Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitroglycerin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitroglycerin SCHEMBL15421 | 1.00 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL28118295 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL3640987 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL27278730 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL7752031 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL28723109 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL10424193 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL3640991 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL7752036 | 0.97 | PTGS2 (0.40) | PTGS2PTGS1ALDH1A1GSR | |
| Nitroglycerin SCHEMBL5490103 | 0.95 | PTGS2 (0.39) | PTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256161-A9 | Methods and Compositions for Treating a Disease Condition in a Subject | Palo Alto Investors LP | 2023-08-17 | — | — | US | disclosed |
| US-11389534-B2 | Methods of treating a subject for a condition | PALO ALTO INVESTORS (US) | 2022-07-19 | — | — | US | disclosed |
| US-11382513-B2 | Methods and compositions for treating a condition in a subject | PALO ALTO INVESTORS (US) | 2022-07-12 | — | — | US | disclosed |
| CN-112807290-A | Novel scopolamine transdermal drug delivery patch | 江苏集萃新型药物制剂技术研究所有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10998091-B2 | Systems for monitoring compliance with a patch dosage regimen and methods of using the same | PATIL SANDEEP (US) | 2021-05-04 | — | — | US | disclosed |
| US-20210121625-A1 | Methods and Compositions for Treating a Disease Condition in a Subject | YUN ANTHONY JOONKYOO (US) | 2021-04-29 | — | — | US | disclosed |
| US-10946197-B2 | Treatment of conditions through modulation of the autonomic nervous system | PALO ALTO INVESTORS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200360271-A1 | Methods and Compositions for Treating a Renal Disease Condition in a Subject | Palo Alto Investors LP | 2020-11-19 | — | — | US | disclosed |
| US-20200258610-A1 | Systems for Monitoring Compliance with a Patch Dosage Regimen and Methods of Using the Same | PATIL SANDEEP (US) | 2020-08-13 | — | — | US | disclosed |
| US-10716749-B2 | Methods and compositions for treating a renal disease condition in a subject | PALO ALTO INVESTORS (US) | 2020-07-21 | — | — | US | disclosed |
| WO-1998028045-A2 | METHOD FOR DESTROYING ENERGETIC MATERIALS | COMMODORE APPLIED TECHNOLOGIES, INC. (US) | 1998-07-02 | — | — | WO | disclosed |
| US-5656286-A | BLEND OF TWO POLYMERS; PRESSURE SENSITIVE ADHESIVE | NOVEN PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5474783-A | In the form of sheet; used for applying to the dermis | NOVEN PHARMACEUTICALS, INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5271940-A | Transdermal delivery device having delayed onset | CYGNUS THERAPEUTIC SYSTEMS (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0249343-B1 | MOISTURE ACTIVATION OF TRANSDERMAL DRUG DELIVERY SYSTEM | ALZA CORPORATION (US) | 1992-01-08 | — | — | EP | disclosed |
| US-4971799-A | Skin delivery device for cardiovascular disorders | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-11-20 | — | — | US | disclosed |
| US-4921695-A | Antianginal plate for treating ischemic heart disease | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY TSENTR PROFILAKTICHESKOI MEDITSINY - USSR | 1990-05-01 | — | — | US | disclosed |
| US-4842854-A | SUSTAINED RELEASE DELIVERY OF DRUG DIRECTLY TO BLOOD | VSESOJUZNY KARDIOLOGICHESKY NAUCHNY TSENTR AKADEMII MEDITSINSKIKI NAUK SSR (SU) | 1989-06-27 | — | — | US | disclosed |
| EP-0249343-A1 | Moisture activation of transdermal drug delivery system | ALZA CORPORATION (US) | 1987-12-16 | — | — | EP | disclosed |
| EP-0249475-A2 | Delayed percutaneous delivery | ALZA CORPORATION (US) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10998091-B2 | Systems for monitoring compliance with a patch dosage regimen and methods of using the same | CUTA, ACHE, PTPN21 | PTGS2 1449/4885PTGS1 1159/4885ALDH1A1 3669/4885 |
| US-20200258610-A1 | Systems for Monitoring Compliance with a Patch Dosage Regimen and Methods of Using the Same | CUTA, ACHE, PTPN21 | PTGS2 1449/4885PTGS1 1159/4885ALDH1A1 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.